Advertisement

Does Physical Activity Play a Role in the Efficacy of RegoNivo for MSS-mCRC?

Published:October 02, 2021DOI:https://doi.org/10.1016/j.clcc.2021.09.011

      Abstract

      Background

      In 2019, researchers reported a remarkable 33% response rate and a median progression free survival of almost 8 months in a study of Regorafenib and Nivolumab (RegoNivo) with 24 Japanese patients with chemo-refractory MSS-mCRC. These clinical outcomes were subsequently not replicated in clinical trials in North America. One hypothesis that has been put forth is that trials in North America had a higher percentage of patients with liver metastases who are less likely to respond to Regorafenib and Nivolumab. We propose an alternate hypothesis reflected by ECOG Performance Status = 0.

      Methods

      We reexamined the available trial data on RegoNivo for MSS-mCRC in the original Japanese trial and compared it to subsequent clinical trials of the same combination and setting in North America.

      Results

      100% of patients on the original Japanese trial were ECOG PS = 0 whereas those in the subsequent trials in North America included a majority of patients with ECOG PS = 1. The percentage of patients with liver metastases is not as clearly different among these trials compared to ECOG PS 0.

      Conclusions

      ECOG PS may represent a composite marker of patient physical activity and/or fitness and disease biology. Although ECOG PS and physical activity are not completely the same, ECOG PS and physical activity of patients has not been fully investigated in the context of response to RegoNivo. Alternatively, it is possible that poor ECOG PS may also reflect unfavorable tumor biology, and such tumors might progress before RegoNivo has a chance to provide clinical benefit

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fukuoka S
        • Hara H
        • Takahashi N
        • et al.
        Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib Trial (REGONIVO, EPOC1603).
        J Clin Oncol. 2020 Jun 20; 38 (Epub 2020 Apr 28. PMID: 32343640): 2053-2061https://doi.org/10.1200/JCO.19.03296
        • Kim R.
        • Imanirad I.
        • Carballido E.
        • Strosberg J.
        • Kim Y.
        • Kim D.
        Phase I/IB study of regorafenib and nivolumab in mismatch repair (MMR) proficient advanced refractory colorectal cancer.
        ESMO World GI. 2020; 31 (SUPPLEMENT, JULY 01, 2020): 239
        • Fakih Marwan
        • Raghav Kanwal Pratap Singh
        • Chang David Z.
        • et al.
        J Clin Oncol. 2021; 39 (suppl 15; abstr 3560)
        • Wang C
        • Chevalier D
        • Saluja J
        • Sandhu J
        • Lau C
        • Fakih M.
        Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer.
        Oncologist. 2020; 25 (AugEpub 2020 May 30. PMID: 32406541; PMCID: PMC7418365): e1188-e1194https://doi.org/10.1634/theoncologist.2020-0161
        • Jang Raymond W.
        • Caraiscos Valerie B.
        • Swami Nadia
        • et al.
        Simple prognostic model for patients with advanced cancer based on performance status.
        J Oncol Practice. 2014; 10: e335-e341
        • Guercio Brendan J.
        • Zhang Sui
        • Ou Fang-Shu
        • et al.
        Associations of physical activity with survival and progression in metastatic colorectal cancer: results from cancer and leukemia group B (Alliance)/SWOG 80405.
        J Clin Oncol. 2019; 37: 2620-2631
      1. NCI Staff. Prescribing exercise as cancer treatment: a conversation with Dr. Kathryn Schmitz. November 12, 2019. https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-survivors-exercise-guidelines-schmitz. Accessed October 24, 2021.

        • Gresham G.
        • Hendifar A.E.
        • Spiegel B.
        • et al.
        Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients.
        npj Digital Med. 2018; 1
        • Cousin S
        • Cantarel C
        • Guegan JP
        • et al.
        Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): a single-arm, open-label, Phase II Trial.
        Clin Cancer Res. 2021 Apr 15; 27 (Epub 2021 Jan 25. PMID: 33495314): 2139-2147https://doi.org/10.1158/1078-0432.CCR-20-3416
        • Li J
        • Cong L
        • Liu J
        The efficacy and safety of regorafenib in combination with Anti-PD-1 antibody in refractory microsatellite stable metastatic colorectal cancer: a retrospective study.
        Front Oncol. 2020 Nov 12; 10 (PMID: 33282742; PMCID: PMC7689210)594125https://doi.org/10.3389/fonc.2020.594125
        • Ballard-Barbash R
        • Friedenreich CM
        • Courneya KS
        • et al.
        Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review.
        J Natl Cancer Inst. 2012 Jun 6; 104 (Epub 2012 May 8. PMID: 22570317; PMCID: PMC3465697): 815-840https://doi.org/10.1093/jnci/djs207
        • Oruç Z
        • Kaplan MA.
        Effect of exercise on colorectal cancer prevention and treatment.
        World J Gastrointest Oncol. 2019 May 15; 11 (PMID: 31139306; PMCID: PMC6522766): 348-366https://doi.org/10.4251/wjgo.v11.i5.348
        • Srikrishna Devabhaktuni
        • Sachsenmeier Kris
        We need to bring R0 < 1 to treat cancer too.
        Genome Med. 2021; 13https://doi.org/10.1186/s13073-021-00940-9